Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sparteine SCHEMBL29352895 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL14029290 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL13646782 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL1753344 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL12573662 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL18468288 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL14331495 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL13531828 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL12301225 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E | |
| Sparteine SCHEMBL22619501 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5100647-A | Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1992-03-31 | — | — | US | claimed |
| US-20230212351-A1 | METHOD FOR PRODUCING BLOCK COPOLYMER COMPRISING CYCLIC ESTER AND EPOXY MONOMERS ARRANGED IN CONTROLLABLE SEQUENCE | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2023-07-06 | — | — | US | disclosed |
| WO-2021043315-A1 | METHOD FOR PRODUCING BLOCK COPOLYMER COMPRISING CYCLIC ESTER AND EPOXY MONOMERS ARRANGED IN CONTROLLABLE SEQUENCE | 华南理工大学 | 2021-03-11 | — | — | WO | disclosed |
| EP-2984117-B1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | IBM (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3004105-B1 | PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE | MAULIDE NUNO (AT) | 2017-09-06 | — | — | EP | disclosed |
| US-9388182-B2 | Process for converting lupanine into sparteine | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-9388182-B2 | Process for converting lupanine into sparteine | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20160096840-A1 | PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096840-A1 | PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-04-07 | — | — | US | disclosed |
| WO-2014191261-A1 | PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2014-12-04 | — | — | WO | disclosed |
| US-8216487-B2 | Copolymer of propylene or ethylene oxide and of an oxirane bearing an ionic group | BATSCAP (FR) | 2012-07-10 | — | — | US | disclosed |
| US-8216487-B2 | Copolymer of propylene or ethylene oxide and of an oxirane bearing an ionic group | BATSCAP (FR) | 2012-07-10 | — | — | US | disclosed |
| US-20110319657-A1 | Process for the Preparation of Formic Acid | BASF SE (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-20090176161-A1 | COPOLYMER OF PROPYLENE OR ETHYLENE OXIDE AND OF AN OXIRANE BEARING AN IONIC GROUP | BLUE SOLUTIONS (FR) | 2009-07-09 | — | — | US | disclosed |
| US-20090176161-A1 | COPOLYMER OF PROPYLENE OR ETHYLENE OXIDE AND OF AN OXIRANE BEARING AN IONIC GROUP | BLUE SOLUTIONS (FR) | 2009-07-09 | — | — | US | disclosed |
| US-7402670-B2 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| US-5621007-A | Method for regulation of transmembrane chloride conductance | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| US-5100647-A | Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1992-03-31 | — | — | US | disclosed |
| US-5100647-A | Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | XDH, OXA1L, AOX1 | CYP2D6 139/4885MEN1 1471/4885KMT2A 1323/4885 |
| US-20160096840-A1 | PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE | SPR, GCLC, GSTP1 | CYP2D6 27/4885MEN1 3941/4885KMT2A 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.